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Background: Human adenovirus (HAdV) is an important pathogen seen in clinical practice.
Long-term studies may help better understand epidemiological trends and changes in circu-
lating genotypes over time.
Purpose: Using a large biobank of samples from hospitalized, adenovirus-positive patients
over a 20-year period, we aimed to analyze long-term epidemiological trends and genotypic
relatedness among circulating HAdV strains.
Methods: Based on samples from hospitalized patients confirmed to be HAdV positive in
Bern, Switzerland, from 1998 to 2017, and on their associated demographic and clinical data,
we identified epidemiological trends and risk factors associated with HAdV infection. HAdV
genotyping was performed by PCR amplification and sequencing of the hypervariable hexon
gene. The obtained sequences were phylogenetically compared with sequences from inter-
national HAdV strains.
Results: HAdV was identified in 1302 samples tested. Cases of HAdV infection were
reported throughout the years with no clear seasonality. Upper respiratory tract samples,
conjunctivitis swabs, and stool had the highest positivity rate (56.2%, 18.7%, and 14.2% of
the cases, respectively). HAdV infection was highest among children ≤4 years old. Increased
number of HAdV cases were observed in years 2009 (n = 110) and 2010 (n =112). HAdV8
was the predominant genotype among patients older than 20 years, and was mostly asso-
ciated with ophthalmic infection. Predominant genotypes among children ≤4 years old were
HAdV1, HAdV2, and HAdV3, which were mostly associated with respiratory tract infec-
tions. Recurring peaks of increased HAdV cases were evidenced every 4 years among
children ≤4 years old.
Conclusion: Our study gives novel insights on long-term epidemiological trends and
phylogenetic relatedness among circulating HAdV strains in Switzerland, country in which
little data on HAdV prevalence and diversity was so far available.
Keywords: adenoviruses, human, molecular epidemiology, clinical infections, genotype
Introduction
Human adenovirus (HAdV) is one of the most important viruses seen in clinical and
public health today. This DNAvirus is associated with a wide range of illnesses ranging
from benign colds to more serious conditions including gastroenteritis, acute respiratory
infections, conjunctivitis, haemorrhagic cystitis, meningoencephalitis,1,2 and can cause
severe disease in both immunocompetent3 and immunocompromised hosts, infections
that sometimes result in death.2,4–7 HAdV is estimated to account for about 2% to 5% of
all respiratory infections worldwide. This virus often causes epidemics and outbreaks,
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especially when associated with either ophthalmic infections
or respiratory tract infections.8–10 It is also known to be
causative of emerging viral respiratory tract infections in
humans,8,11-14 along with Middle East respiratory syndrome
coronavirus, H7N9 influenza A virus or swine-like influenza
H3N2 variant virus.
HAdV comprises over 100 genotypes recognized by
the Human Adenovirus Working Group, July 2019,
Update (http://hadvwg.gmu.edu) classified into seven spe-
cies (HAdV-A to HAdV-G). In clinical diagnostics
laboratories, molecular typing of HAdV positive samples
is not routinely performed, unless epidemiological ana-
lyses are conducted. PCR-based techniques targeting
genes encoding for the hypervariable hexon, fiber, penton
base or DNA polymerase, and/or sequencing of their
PCR products, allow identification of HAdV species and
genotypes.
The recent emergence of the HAdV14 strains in the
USA15 and Europe (Ireland)4 calls for a need to fill
major gaps in understanding the molecular epidemiology
and disease patterns of HAdVs. The predominant HAdV
genotypes detected in association with clinical presenta-
tion differ among different countries and may change
over time.16 Currently in Switzerland, the knowledge
on the molecular epidemiology and clinical presentation
of HAdV infection is lacking. This study presents the
molecular epidemiology of HAdV and associated clinical
findings based on a retrospective observational study
from laboratory confirmed HAdV cases collected
between 1998 and 2017, at the Institute for Infectious
Disease (IFIK), following referral of specimens by clin-
icians from the largest hospitals and other regional
clinics in Bern. Since outbreaks of HAdV have been
reported in various countries,10,15,17-19 we therefore
hypothesized that a thorough epidemiological analysis
of the Bern HAdV clinical bio-bank, including genotyp-
ing and comparison to strains involved in international
outbreaks, would provide information on potential out-
breaks of HAdV that occurred in the last 20 years in
Switzerland and how the epidemiological situation com-
pares to that seen elsewhere in Europe during the studied
period. To our knowledge, this is the first study to report
HAdV epidemiology from a large clinical dataset over
a 20-year period from patients of any age with positive
HAdV infection. Overall, the study sheds light on epide-
miological trends, risk factors for infection, and molecu-
lar epidemiology of HAdV circulating genotypes.
Materials and Methods
Laboratory Setting, Study Design and
Ethical Approval
The institute for infectious diseases (IFIK), university of
Bern, is a diagnostic, teaching and research institute in
Switzerland. The institute covers the entire spectrum of
microbiological diagnostics and also provides university
education in clinical microbiology to students studying
human medicine, dentistry, pharmacy, and cell biology.
Samples used in this study are part of the IFIK clinical bio-
bank and consisted of previously screened patient samples
referred to the IFIK for diagnostics purposes by physicians
from the Inselspital and other regional clinics in Bern. The
clinical bio-bank consisted of patient samples and informa-
tion on HAdV cases since 1998. The results of all cases
were extracted from the electronic health-care records and
information such as laboratory I.D., patient I.D., demo-
graphic data (age and sex), screening tests done, and sample
type, which were available for most samples. Archived
patients’ samples were approved for this research by the
Swiss Ethics Committees on Research involving humans
(BASEC-Nr: Req-2018-00158).
Study Population
HAdV positive infection was identified as sample(s)
screened by either viral culture, immuno-chromatographic
rapid test, immunofluorescence (IF), PCR (quantitative or
qualitative real-time PCR), or all of the mentioned methods
tested positive for HAdV by the department of clinical
microbiology at IFIK. In instances in which more than
one sample type was obtained from the same patient in
a given year, multiple patient entries were removed and
only the first screened positive sample type was kept for
a given year. Similarly, subsequent HAdV infections from
the same patient within a given year were excluded from
epidemiological analyses.
Clinical Variables and Definitions
Patient age was defined at the date of sample collection.
Clinical information and severity of HAdV positive cases
were categorized as respiratory tract infection, fever only,
ophthalmic infection, gastrointestinal infection, immuno-
suppressed, severe infection, co-infection, urinary tract
infection, oncological disease, other manifestations, and
unknown/no clinical information provided (Table 1).
Akello et al Dovepress
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Statistical Analysis
The Chi-square test was used to test for significant differ-
ences between categorical variables (test of independence).
Logistic regression was used to determine significant years
associated with increased HAdV cases. Data analysis was
performed with the statistical R environment, version
1.0.153.
DNA Extraction, PCR, and Sequencing
ViralDNAwas extracted from200μLof either original sample
or cell culture supernatant of HAdV positive samples with the
Boom extraction method20 or the NUCLISENS easyMAG
(bioMérieux, Geneva, Switzerland) extractor, as per manufac-
tures instructions, and finally eluted in 50 μL. A PCR proce-
dure that targeted the hypervariable regions 1–7 of the hexon
gene was performed, according to Sarantis and colleagues.21
M13 universal priming tails (forward, 5′-TGTAAAACGAC
GGCCAGT-3′; and reverse, 5′-CAGGAAACAGCTATGA
CC-3′) were added to the Sarantis and colleagues primers
(forward, 5′- CTGATGTACTACAACAGCACTGGCAACA
TGGG-3′; and reverse 5′- GCGTTGCGGTGGTGGTTAA
ATGGGTTTACGTTGTCCAT-3′). A standard protocol of
the ZymoTaq Hotstart DNA PCR was applied, consisting of
2× Zymo reaction buffer, 0.2 mM dNTP mix, 0.5 µM of each
primer, 5 U/µL ZymoTaq DNA Polymerase, 10 µL of DNA
template and water up to 50 µL. Thermal cycling conditions
were 95°C for 10mins, 37 cycles at 95°C for 30 secs, 51°C for
30 secs, and 72°C for 1min,with afinal extension at 72°C for 7
mins. PCR products were resolved and visualized by electro-
phoresis on 1% agarose gel stained with RedSafe DNA Gel
Stain (Invitrogen, Switzerland). Expected amplicon sizes ran-
ged from602 to 630 bp. Sampleswith PCRproduct band of the
expected size were purified using 1.8× Agencourt Ampure XP
beads (Beckman Coulter, Nyon, Switzerland), quantified by
Qubit 3.0 fluorometer (ThermoFisher Scientific, Reinach,
Switzerland), diluted to concentration of 180 ng in total reac-
tion volume of 12 µL and then submitted to Microsynth AG
(Balgach, Switzerland) for Sanger sequencing. All sequence
data were deposited to the European Nucleotide Archive,
under project reference PRJEB36200.
Sequence and Phylogenetic Analysis
The forward and reverse sequences were trimmed and
assembled using DNASTAR Lasergene SeqMan Pro ver-
sion: 7.1.0 (44.1). The consensus sequence of each sample
obtained was blasted against all HAdV sequences avail-
able in GenBank to identify the species and genotype. The
phylogenetic trees were constructed using the Neighbor-
Joining method based on evolutionary distances computed
using the number of differences method. MEGA-X22 was
used to generate phylogenetic trees and evaluate topolo-
gies with 1000 bootstrap replicates.
Table 1 Definition of Clinical Categories Used in the Study
Clinical Category Clinical Features
Co-infection Respiratory syncytial virus, Haemophilus influenzae
Fever only Fever
Gastrointestinal infection Diarrhoea, vomiting, abdominal pain. Rare complications include haemorrhagic colitis, enteritis, hepatitis, cholecystitis,
and pancreatitis
Immunosuppressed Acute myeloid leukaemia, acute lymphatic leukaemia, chronic lymphatic leukaemia, esophagitis HIV stage III, after
kidney transplant, after liver transplant, HIV positive, chemotherapy, immunosuppressed
Ophthalmic infection Epidemic keratoconjunctivitis, pharyngoconjunctival fever, and nonspecific conjunctivitis
Other infection Exanthema, mononucleosis-like syndromes, leukocytosis, anaemia
Respiratory tract infection Fever, pharyngitis, tonsillitis, cough, sore throat, pneumonia, bronchitis, rhinitis, angina, sinusitis
Severe infection Encephalitis, meningitis, myocarditis and cardiomyopathy, intestinal intussusception, disseminated infection, sudden
infant death syndrome
Unknown Missing clinical information
Urinary tract infection Dysuria, haematuria, haemorrhagic cystitis, and renal allograft dysfunction
Dovepress Akello et al
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Results
Descriptive Epidemiology of HAdV Cases
in Bern
We analysed samples that were referred to the IFIK for HAdV
screening from January 1998 to December 2017. Of the
43,562 samples screened for HAdV from suspected patients,
34,556 (79.3%) samples were identified as unique patient
cases based on patient I.D. and year of entry. Based on the
laboratory confirmed results, 1302 (3.8%) were identified as
positive. Of the 1302 HAdV positive cases, one case had
information missing on age, gender, and clinical information,
and was thus excluded from further analysis. The median age
of HAdV positive patients was 3 years (range 0 months – 100
years; Table 2). A significant difference in the number of
HAdV positive cases among males and females was observed
(P < 0.001) with females accounting for 42.4% (552/1301) of
the cases. A significant difference in the frequency of positive
HAdV cases among the different age groups was also
observed (P < 0.001), with the highest number of HAdV
positive cases being found among young children aged ≤4
years (744; 57.2%), followed by those in the age group 20–44
years old (163; 12.5%). The least age group (59; 4.5%)was for
children between 5 and 9 years. Logistic regression analyses
confirmed that the overall effect of age category was statisti-
cally significant in determining positivity for HAdV infection
as compared to those aged ≤4 years (P < 0.001).
The yearly positive rate for HAdV ranged from 2.0% to
6.1%, with an average rate of 3.9%. A peak in proportion of
HAdV positive cases was observed in years 1998 (5.6%),
2001 (5.9%), 2003 (5.2%), 2005 (5.5%), 2009 (4.8%), and
2010 (6.1%). An increased number of HAdV positive cases
Table 2 Characteristics of the Study Population
Demographic Characteristic N (%)
HAdV Positive Cases 1301a (100)
Gender
Female 552 (42.4)
Male 747 (57.4)
Unknown 2 (0.15)
Age Category (Years)
0–4 744 (57.2)
5–9 131 (10.1)
10–19 59 (4.5)
20–44 163 (12.5)
(Continued)
Table 2 (Continued).
Demographic Characteristic N (%)
45–64 124 (9.5)
65–100 80 (6.2)
Sample Types
Upper respiratory tract 731 (56.2)
Conjunctivitis swab 243 (18.7)
Stool 184 (14.1)
Swab 59 (4.5)
Lower respiratory tract 48 (3.7)
Other 19 (1.5)
Genital swab 7 (0.5)
Blood 5 (0.4)
Unknown 5 (0.4)
Clinical Presentation and Comorbidities
Respiratory tract infection 388 (29.8)
Unknown/missing 268 (20.6)
Ophthalmic infection 212 (16.3)
Fever 165 (12.7)
Gastrointestinal infection 93 (7.1)
Immunosuppressed 39 (3.0)
Respiratory tract infection + Gastrointestinal infection 30 (2.3)
Severe infection 16 (1.2)
Other infection 16 (1.2)
Respiratory tract infection + Immunosuppressed 12 (0.9)
Respiratory tract infection + Ophthalmic infection 11 (0.8)
Co-infection 7(0.5)
Respiratory tract infection + Other infection 6 (0.5)
Respiratory tract infection + Co-infection 5 (0.4)
Urinary tract infection 4 (0.3)
Gastrointestinal infection + Other infection 4 (0.3)
Respiratory tract infection + Urinary tract infection 4 (0.3)
Gastrointestinal infection + Urinary tract infection 3 (0.2)
Fever + Other infection 3 (0.2)
Oncological disease 2 (0.2)
Gastrointestinal infection +Immunosuppressed 2 (0.2)
Gastrointestinal infection + Severe infection 2 (0.2)
Respiratory tract infection + Severe infection 2 (0.2)
Ophthalmic infection + Co-infection 1 (0.1)
Severe infection + Immunosuppressed 1 (0.1)
Respiratory tract infection + Gastrointestinal infection
+ Other infection
1 (0.1)
Respiratory tract infection + Gastrointestinal infection
+ Urinary tract infection
1 (0.1)
Respiratory tract infection + Ophthalmic infection +
Co-infection
1 (0.1)
Respiratory tract infection + Ophthalmic infection +
Gastrointestinal infection
1 (0.1)
Respiratory tract infection + Ophthalmic infection +
Other infection
1 (0.1)
Note: aThe total of 1301 corresponds to 3.76% of the total suspected HAdV cases
over the 20-year period.
Akello et al Dovepress
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occurred in years 2009 and 2010, with 110 and 112 cases,
respectively (Figure 1A). A heat map of the monthly inci-
dence showed that HAdV appeared to occur throughout
the year. Although the data showed no clear seasonality,
a pattern reminiscent of HAdVoutbreaks was observed par-
ticularly in January 2010 (n = 24), July 2009 (n = 33), and
March 1998 (n = 24). Themean expected incidence of HAdV
cases per month from 1998 to 2017 was 5.43 cases (95% CI,
1.86–12.26 cases). Therefore, HAdV incidence of ≥13 cases
was defined as significantly higher number than the mean
expected incidence (Figure 1B).
Upper respiratory tract samples were the most common
positive sample types (N = 731; 56.2%), followed by
conjunctivitis swab (243; 18.7%), and stool (184; 14.1%).
HAdV was least detected from EDTA blood and genital
swab samples. Higher numbers of positive conjunctivitis
swab samples were observed in years 2009 and 2010 than
in any other year (Figure 2A). Among young children,
upper respiratory tract and stool samples were associated
with the largest number of positive cases, whilst conjuncti-
vitis swab samples were the most positive among young
adults, middle aged and elderly (Figure 2B). A peak in
HAdV cases was also observed between the years 2009
and 2010, as compared to other years in the study period,
across all age categories. The most unexpected finding was
a peak in the number of HAdV cases reoccurring every 4
years among children ≤4 years old, with increased inci-
dences during the years 1998, 2001, 2002, 2006, 2010,
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and 2014, with an average rate of 3.91% (Figure 3A
and 3B).
Molecular Typing of Cases Associated
with Increased Incidence in Years 2009
and 2010
Of the 222 HAdV positive samples, 154 (69.4%) samples
were available for HAdV molecular typing. Out of the 154
samples subjected to typing, HAdV genotypes were identified
in 145 samples, including 63 (43.4%) samples from patients
aged 0–4 years, 8 (5.5%) from 5 to 9-year-olds, 5 (3.4%) from
10 to 19-year-olds, 21 (14.5%) from 20 to 44-year-olds,
21 (14.5%) from 45 to 64-year-olds, and 27 (18.6%) from
65 to 100-year-olds. Fourteen HAdV genotypes were identi-
fied to be circulating during this time period (Figure 4A), with
10 and 11 different HAdV genotypes identified in the years
2009 and 2010, respectively. The predominant circulating
types in these 2 years were HAdV8 (63; 43.4%), HAdV2
(31; 21.4%), HAdV1 (21; 14.5%), and HAdV3 (11; 7.6%),
B
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with HAdV species D genotypes accounting for the majority
(48.3%) of the cases. However, in the year 2010 only, HAdV2
belonging to HAdV species C became the predominant geno-
type accounting for 29.9% (20/67) of the cases, followed by
HAdV8 with 26.9%, and HAdV1 with 16.4% of the cases.
Genotypes HAdV41, HAdV56, and HAdV64 were detected
in the year 2009 only, whilst HAdV6, HAdV7, HAdV28, and
HAdV53were detected in the year 2010 only. Among samples
from those aged 0–4 years (n = 63), HAdV2 (46.0%), HAdV1
(30.2%), HAdV3 (7.9%), and HAdV5 (6.3%) were the main
genotypes. Among samples from 5 to 9-year-olds (n = 8),
HAdV3 (50.0%) was the main genotype. HAdV8 was the
predominant genotype, accounting for 40.0%, 71.4%, 85.7%,
and 100% of the cases, among samples from 10–19, 20–44,
45–64, and 65–100-year-olds, respectively (Figure 4B).
HAdV cases with ophthalmic infection (n = 36),
respiratory tract infection (n = 36), and with unknown/
missing clinical information (n = 51), accounted for the
majority of the genotyped samples (Figure 4C). Most
cases presenting with ophthalmic infection (88.8%) and
those with unknown/missing clinical information (74.5%)
were identified to be infected with HAdV species
D genotypes, particularly HAdV8. HAdV cases presenting
with respiratory tract infection were associated with
HAdV species C genotypes (HAdV1, HAdV2, and
HAdV5), and HAdV species B genotype (HAdV3).
Similarly, the former HAdV species C genotypes were
also found in patients presenting with fever. Among
patients presenting with gastrointestinal infection,
HAdV2, HAdV3 and HAdV41 were identified. HAdV6
was identified in a case presenting with immune suppres-
sion. Among those who had more than one clinical pre-
sentation and comorbidity (ie, respiratory tract infection
and gastrointestinal infection, respiratory tract infection
and immune suppression, respiratory tract infection and
co-infection), HAdV2 and HAdV3 were identified.
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numbers of HAdV cases. In panel B, the dotted line represents the overall average number of cases.
Dovepress Akello et al
Clinical Epidemiology 2020:12 submit your manuscript | www.dovepress.com
DovePress
359
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
92
.7
4.
86
 o
n 
25
-M
ay
-2
02
0
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Molecular Epidemiology of HAdV
Between 1998 and 2017 in Young Children
Out of the 745 identified positive samples from young children
(≤4 years old) during years 1998 −2017, 198 (26.6%) were
available for typing. We identified a wide variety of HAdV
genotypes circulating among young children during this per-
iod (Figure 5A), with HAdV1 (n = 49), HAdV2 (n = 93),
HAdV3 (n = 17), and HAdV41 (n = 13) being the most
common HAdV genotypes accounting for 24.7%, 47.0%,
8.6%, and 6.6% of the cases, respectively. Most typed samples
were from the years 2010 (n = 38), 2009 (n = 25), 2006
(n = 24), 2002 (n = 15), 2001 (n = 17), and 2000 (n = 15).
We did not identify instances of co-infection with different
genotypes of HAdV. The majority of HAdV genotypes were
identified among those presenting with respiratory tract infec-
tions, fever, gastrointestinal infection, and missing clinical
information (Figure 5B). HAdV2, HAdV5 and HAdV1 were
identified in three dead young children (≤4 years old) in years
2006, 2012, and 2014, respectively. All three cases were
associated with sudden infant death syndrome.
Phylogenetic Analysis
The nucleotide sequences of the partial hypervariable hexon
gene 1–7 from HAdV genotypes identified in this study were
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aligned and analysed with sequences from circulating HAdV
genotypes identified in China including Taiwan, Egypt,
France, Germany, Japan, Korea, Russia, Sweden, and the
USA (Figure 6). The phylogenetic analysis showed that the
sequences of the HAdV genotypes (HAdV1, HAdV2,
HAdV3, HAdV4, HAdV5, HAdV6, HAdV7, HAdV8,
HAdV28, HAdV37, HAdV41, HAdV53, HAdV56, and
HAdV64) identified in the years 2009 and 2010 in this
study from patients of all ages clustered with other interna-
tional sequences of similar HAdV genotypes and exhibited
similarity >98% at the nucleotide level. Similarly, phyloge-
netic analysis of the 14 HAdV genotypes identified among
young children ≤4 years infected with HAdV from years 1998
to 2017 in our study clustered with international sequences of
the same HAdV genotypes (Figures S1A and B).
Discussion
Our 20-year retrospective observational study from
patients across all age categories underlines the need to
carry epidemiological studies and molecular typing of
HAdV among patients with HAdV infection. Although
long-term epidemiological trends demonstrated no clear
seasonality, a pattern reminiscent of recurring outbreaks
was evidenced with high number of HAdV cases observed
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in January 2010, July 2009 and March 1998 as compared
to other months or years during the study period.
Genotyping of samples from years 2010 and 2009 identi-
fied HAdV8 as predominant genotype causing HAdV
infection among young adults, middle-aged and elderly,
and HAdV1 and HAdV2 as predominant genotypes
causing HAdV infection among young children.
Although HAdV infections are known to fluctuate over
time, increased cases of HAdV infections were evidenced
among young children every 4 years. This study is the first
to report such recurring pattern. Previously, Heo and
colleagues23 showed that cases of HAdV respiratory
Figure 6 Phylogenetic tree of HAdV genotypes detected among patients of all ages from January 2009 to December 2010. Sequences from years 2009 and 2010 isolates are
represented by red triangles and blue circles, respectively. The analysis involved 193 nucleotide sequences (145 HAdV sequences from patients in this study and 48 reference
strains). Reference strains are indicated in bold font with their GenBank accession number. The scale bar indicates the number of nucleotide differences per sequence.
Percentage bootstrap supports are indicated on each node of the tree.
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infection are common during winter and spring. A study
by Yao and colleagues concluded that HAdV prevalence
may be related to age and season.24 Our findings suggest
that increased HAdV infection in Switzerland was related
to age, but to a lesser extent to a particular season, as
HAdV infections occurred throughout the year. Also when
detected, HAdV was predominantly found among those
aged ≤4 years. HAdV is therefore confirmed to be an
important pathogen in clinical practice, mainly in the
paediatric population.
The high incidence of HAdV8 associated with ophthal-
mic infections among young adults, middle-aged and elderly
in the years 2009 and 2010 is consistent with what was seen
in Germany for instance.25 Our finding is also consistent with
other studies that showed HAdV8 to be a major culprit of
adenovirus-associated conjunctivitis.9,26,27 In addition, the
predominance of HAdV species C genotypes, particularly
HAdV1 and HAdV2, found among young children is also
supported by other studies.28 As young children have devel-
oping immune system, they may be more prone to infections.
In the same line of evidence, most HAdV infections in
immunocompromised hosts are known to be associated
with HAdV species C genotypes 1 and 2.14,29 Our study
focused on molecular typing of HAdV positive samples
collected between 1998 and 2017 among young children ≤4
years in order to identify the genotypes associated with an
increase of cases of HAdV infection among this age category
every 4 years. Various genotypes were identified to be caus-
ing HAdV infections, among which HAdV1 and HAdV2
genotypes were predominantly detected in the years with
reoccurring peaks. These genotypes were also observed in
the non-reoccurring peaks, but to a lesser extent. These
typing results give insight into circulating HAdV genotypes
causing disease mainly among young children who are
known to be at high risk of HAdV infection.
Although patients from all age categories may be suscep-
tible to HAdV infections, more cases of HAdV infections in
this study were observed among children ≤4 years old.
HAdV species C genotypes (HAdV1, HAdV2, and
HAdV5) and HAdV species B genotype (HAdV3) were the
most commonly identified genotypes, indicating that young
children may be particularly sensitive to these genotypes.
Previous studies have shown that HAdV infections in
young children may be severe, including manifestations ran-
ging from meningitis, intussusception, subacute focal ence-
phalitis and myocarditis, to disseminated disease, or even
death.30–33 Of particular note to this study are the five
patients with HAdV infection who died in the 20-year period.
Four patients who died were aged ≤4 years (three males and
one female) and one patient was a 6-year-old male. Our data
showed that, of the three patients who died and whose
samples were available for typing, one had been infected
with HAdV1, one had been infected with HAdV2, and one
had been infected with HAdV5. All three patients presented
with sudden infant death syndrome. The case of another
patient aged ≤4 years who died suffering from disseminated
adenoviral infection with hepatitis, but whose sample was
not available in this study for typing, was reported by Steiner
and colleagues.34 Although HAdV infections are usually
self-limited and mild, several studies implicating HAdV
causing fatal cases have been reported.5,6,35
The association between HAdV genotypes and clinical
presentations and comorbidities in infected patients have
been examined in several studies: Wurzel and colleagues
found that HAdV species C genotypes (HAdV1 and
HAdV2) are predominant in the airways of young children
and are therefore a likely etiological agent of the disease.36
Wang and colleagues showed that only HAdV B, C
and E were identified among children with significant
respiratory symptoms.37 Furthermore, Liu and colleagues
reported that HAdV species B genotypes (HAdV3 and
HAdV7) are predominant genotypes among paediatric popu-
lation presenting with acute lower respiratory tract
infections.38 A strong association of HAdV40 and HAdV41
with gastroenteritis is known. In our study, we noticed that,
besides these genotypes, other HAdV genotypes were iden-
tified in those presenting with gastrointestinal infection
(Figure 5B), a finding that is similar to what was reported
by Kumthip and colleagues.39 In addition, it is known that
specific HAdV species have distinct tissue tropism which
may determine the clinical presentation.40
The presence of HAdV in respiratory tract and stool
samples from patients not presenting with any clinical
symptoms might be detected incidentally, thus making
interpretation of the clinical significance of a positive
result difficult. Yet, in our study, samples of the patients
who had any clinical presentation associated with HAdV
infection were referred for laboratory diagnostics testing to
our institute upon the request of the seeing physician when
an adenovirus infection was suspected. Therefore, majority
of the HAdV positive, hospitalized patients in this study
had an adenovirus associated clinical presentation.
Persistence of HAdV in a latent state among young chil-
dren has been described.41–43 Reports of asymptomatic
individuals shedding virus into the stool was also
described.41,44,45 In our study, 86.1% of young children
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≤4 years old whose stool sample tested positive for HAdV
had a clinical presentation, with gastrointestinal infection,
fever, and respiratory tract infection being the most pre-
dominant clinical presentations.
The phylogenetic analysis showed that the sequences of
HAdV genotypes identified in our study displayed great
similarity with nucleotide sequences from HAdV genotypes
isolated in other countries. Although this finding may indi-
cate that the same circulating genotypes may be found at the
global scale, we cannot exclude that the partial sequences of
the hypervariable hexon gene does not allow enough resolu-
tion among genotypes. As such, targeting other regions of the
HAdV genomes such as fiber, penton base, and/or DNA
polymerase genes may provide further information on differ-
ences among circulating HAdV genotypes, may help clarify
the HAdV genotypes and also identify recombination events.
Our study has a number of limitations. First, our
reported trends likely underestimate the true burden of
HAdV infections in both the hospitalized patients and in
the community, as samples sent for laboratory diagnostic
testing to the IFIK rely on request by physicians, when an
adenovirus infection is suspected. Second, samples were
tested using different diagnostic methods for HAdV and
some methods are known to be less sensitive for HAdV
detection than others.46 Therefore, there is a chance that this
could have also affected the results of our study. Third,
some of the clinical information was missing, hence
restricting interpretation of trends in HAdV clinical presen-
tation associated with circulating genotypes. In addition,
clinical information was obtained from electronic clinical
records provided to the IFIK diagnostic department and
could not be improved in most of the cases. Fourth, several
HAdV positive samples could not be genotyped due to
unavailability/lack of sample material. Although the miss-
ing information was not systematic for a particular age
group, sample type or year, the unavailable information
might have biased our results and therefore, the reported
HAdV genotypes might not be fully representative of cir-
culating HAdV genotypes in a given year. In addition,
a complete quantitative description of the main genotype
(s) causing an increase in HAdV infection every 4 years
among young children could not be reached due to this lack
of samples.
In conclusion, our study gives insight on HAdV infec-
tions from the largest hospital in Bern and other regional
clinics serving the Swiss population. Patients of various
age categories were identified to be infected, with peak
years in 2009 and 2010. In these 2 years, HAdV8 was
identified as the predominant genotypes and was asso-
ciated with HAdV infections among young adults, middle
aged and the elderly, whilst HAdV2 and HAdV1 geno-
types were identified to be predominantly causing HAdV
infection among young children. The findings support that
variation in the clinical presentation and epidemiology of
HAdV genotypes exists, and may present unexpected pat-
terns when long-term records are examined. By uncover-
ing HAdV molecular epidemiology and its clinical
presentations in our 20-year observation study, we have
highlighted the existence of differences in HAdV infec-
tions among various age categories and circulating HAdV
genotypes. Future work will be performed to sequence the
whole genomes of representative HAdV isolates to assess
the recombination potential in our strain collection.
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